Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.